Name of applicant:
|
GSK plc
|
|||
Name of scheme:
|
GlaxoSmithKline plc 2017 Deferred Annual Bonus Plan
|
|||
Period of return:
|
From:
|
1 November 2023
|
To:
|
30 April 2024
|
Balance of unallotted securities under scheme(s) from previous
return:
|
271,307
|
|||
Plus: The
amount by which the block scheme(s) has been increased since the
date of the last return (if any increase has been applied
for):
|
0
|
|||
Less: Number
of securities issued/allotted under scheme(s) during
period (see LR3.5.7G):
|
155,789
|
|||
Equals: Balance
under scheme(s) not yet issued/allotted at end of
period:
|
115,518
|
Name of applicant:
|
GSK plc
|
|||
Name of scheme:
|
GlaxoSmithKline plc Share Save Plan 2012
|
|||
Period of return:
|
From:
|
1 November 2023
|
To:
|
30 April 2024
|
Balance of unallotted securities under scheme(s) from previous
return:
|
506,598
|
|||
Plus: The
amount by which the block scheme(s) has been increased since the
date of the last return (if any increase has been applied
for):
|
2,000,000
|
|||
Less: Number
of securities issued/allotted under scheme(s) during
period (see LR3.5.7G):
|
1,833,574
|
|||
Equals: Balance
under scheme(s) not yet issued/allotted at end of
period:
|
673,024
|
Name of applicant:
|
GSK plc
|
|||
Name of scheme:
|
GlaxoSmithKline plc Share Save Plan 2022
|
|||
Period of return:
|
From:
|
1 November 2023
|
To:
|
30 April 2024
|
Balance of unallotted securities under scheme(s) from previous
return:
|
999,109
|
|||
Plus: The
amount by which the block scheme(s) has been increased since the
date of the last return (if any increase has been applied
for):
|
0
|
|||
Less: Number
of securities issued/allotted under scheme(s) during
period (see LR3.5.7G):
|
3,852
|
|||
Equals: Balance
under scheme(s) not yet issued/allotted at end of
period:
|
995,257
|
Name of contact:
|
Victoria Whyte
|
Telephone number of contact:
|
020 8047 5000
|
|
GSK plc
|
|
(Registrant)
|
|
|
Date: May
13, 2024
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GSK plc
|